Robert James Kane Sells 1,389,577 Shares of Cannabis Science Inc (CBIS) Stock
Cannabis Science Inc (OTCMKTS:CBIS) CFO Robert James Kane sold 1,389,577 shares of the stock in a transaction that occurred on Friday, October 14th. The stock was sold at an average price of $0.02, for a total value of $27,791.54. Following the transaction, the chief financial officer now owns 21,537,665 shares in the company, valued at approximately $430,753.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Robert James Kane also recently made the following trade(s):
- On Monday, October 10th, Robert James Kane sold 1,783,475 shares of Cannabis Science stock. The stock was sold at an average price of $0.02, for a total value of $35,669.50.
- On Tuesday, September 13th, Robert James Kane sold 2,000,000 shares of Cannabis Science stock. The stock was sold at an average price of $0.01, for a total value of $20,000.00.
Cannabis Science Inc (OTCMKTS:CBIS) traded up 29.032% during trading on Monday, hitting $0.032. The stock had a trading volume of 75,661,707 shares. Cannabis Science Inc has a 12-month low of $0.01 and a 12-month high of $0.03. The stock’s 50 day moving average price is $0.02 and its 200 day moving average price is $0.02. The firm’s market cap is $62.95 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/robert-james-kane-sells-1389577-shares-of-cannabis-science-inc-cbis-stock.html
Cannabis Science Company Profile
Cannabis Science, Inc is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Receive News & Ratings for Cannabis Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannabis Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.